Acura Pharmaceuticals Inc
Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminoph… Read more
Acura Pharmaceuticals Inc (ACUR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2021: 1.415x
Based on the latest financial reports, Acura Pharmaceuticals Inc (ACUR) has a cash flow conversion efficiency ratio of 1.415x as of September 2021.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($191.00K) by net assets ($135.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Acura Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2007–2021)
This chart illustrates how Acura Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Acura Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Acura Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ZIL Ltd
KAR:ZIL
|
N/A |
|
Record PLC
LSE:REC
|
0.126x |
|
PAVmed Inc. Series Z Warrant
NASDAQ:PAVMZ
|
-0.039x |
|
CRFB3F
SA:CRFB3F
|
N/A |
|
HAPV3F
SA:HAPV3F
|
N/A |
|
HB Solution Co. Ltd.
KO:297890
|
N/A |
|
Inflection Point Acquisition Corp. II Warrant
NASDAQ:IPXXW
|
N/A |
|
King House CO., Ltd.
TWO:4419
|
0.098x |
Annual Cash Flow Conversion Efficiency for Acura Pharmaceuticals Inc (2007–2021)
The table below shows the annual cash flow conversion efficiency of Acura Pharmaceuticals Inc from 2007 to 2021.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2021-12-31 | $178.00K | $-742.00K | -4.169x | -3515.42% |
| 2020-12-31 | $-5.89 Million | $-719.00K | 0.122x | -6.37% |
| 2019-12-31 | $-4.74 Million | $-618.00K | 0.130x | -87.94% |
| 2018-12-31 | $-3.62 Million | $-3.91 Million | 1.080x | -99.35% |
| 2017-12-31 | $-27.00K | $-4.51 Million | 167.037x | +3652.13% |
| 2016-12-31 | $1.18 Million | $-5.56 Million | -4.702x | -907.30% |
| 2015-12-31 | $7.90 Million | $-3.69 Million | -0.467x | +78.64% |
| 2014-12-31 | $5.05 Million | $-11.04 Million | -2.186x | -186.45% |
| 2013-12-31 | $17.92 Million | $-13.68 Million | -0.763x | -199.60% |
| 2012-12-31 | $27.63 Million | $-7.04 Million | -0.255x | -175.81% |
| 2011-12-31 | $36.64 Million | $12.31 Million | 0.336x | +197.15% |
| 2008-12-31 | $37.06 Million | $4.19 Million | 0.113x | -88.99% |
| 2007-12-31 | $18.72 Million | $19.22 Million | 1.027x | -- |